Literature DB >> 15009863

Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy.

Michael C Giudici1, Deborah L Paul, Praveen Bontu, S Serge Barold.   

Abstract

The study evaluated all patients undergoing permanent pacemaker and ICD implantation over a 4-year period to determine if anticoagulated patients required normalization of coagulation factors in the periprocedural period. The study included 1,025 (597 men, 428 women, age 24-100 years, mean 72 years) consecutive patients who underwent device implantation using mostly a percutaneous subclavian approach. The procedures were performed without reversal of anticoagulation in 470 patients with INRs >or= 1.5 at the time of the procedure (mean INR 2.6 +/- 1.0, range 1.5-7.5). The complication rate in the anticoagulated group was similar to those in patients with a normal INR. Routine normalization of coagulation factors prior to pacemaker/ICD placement may not be necessary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009863     DOI: 10.1111/j.1540-8159.2004.00441.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  10 in total

Review 1.  Meta-analysis of bleeding complications associated with cardiac rhythm device implantation.

Authors:  Michael L Bernard; Matthew Shotwell; Paul J Nietert; Michael R Gold
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-04-24

Review 2.  [Strategies for the avoidance and treatment of complications during pacemaker implantation].

Authors:  C Kolb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

Review 3.  Safety of Anticoagulation Interruption in Patients Undergoing Surgery or Invasive Procedures: A Systematic Review and Meta-analyses of Randomized Controlled Trials and Non-randomized Studies.

Authors:  Frédérique Hovaguimian; Sabrina Köppel; Donat R Spahn
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

4.  Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation.

Authors:  Imdad Ahmed; Elie Gertner; William B Nelson; Chad M House; Dennis W X Zhu
Journal:  J Interv Card Electrophysiol       Date:  2010-10-13       Impact factor: 1.900

5.  Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device.

Authors:  Shivanshu Madan; Purushothaman Muthusamy; Katie L Mowers; Darryl A Elmouchi; Bohuslav Finta; Andre J Gauri; Alan K Woelfel; Timothy D Fritz; Alan T Davis; Nagib T Chalfoun
Journal:  Cardiovasc Diagn Ther       Date:  2016-02

Review 6.  My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation.

Authors:  Siva Krothapalli; Prashant D Bhave
Journal:  J Atr Fibrillation       Date:  2014-10-31

7.  Antithrombotic or anti-platelet agents in patients undergoing permanent pacemaker implantation.

Authors:  Chang Kun Lee; Sang Yong Yoo; Man Yong Hong; Jin Kun Jang
Journal:  Korean Circ J       Date:  2012-08-31       Impact factor: 3.243

8.  Predictors of pocket hematoma after cardiac implantable electronic device surgery: A nationwide cohort study.

Authors:  Sie Kronborg Fensman; Erik Lerkevang Grove; Jens Brock Johansen; Ole Dan Jørgensen; Maria Hee Jung Park Frausing; Rikke Esberg Kirkfeldt; Jens Cosedis Nielsen
Journal:  J Arrhythm       Date:  2022-08-18

9.  Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial.

Authors:  Jose M Tolosana; Paola Berne; Lluis Mont; Magda Heras; Antonio Berruezo; Joan Monteagudo; David Tamborero; Begoña Benito; Josep Brugada
Journal:  Eur Heart J       Date:  2009-05-31       Impact factor: 29.983

10.  Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices.

Authors:  Kohei Ishibashi; Koji Miyamoto; Tsukasa Kamakura; Mitsuru Wada; Ikutaro Nakajima; Yuko Inoue; Hideo Okamura; Takashi Noda; Takeshi Aiba; Shiro Kamakura; Wataru Shimizu; Satoshi Yasuda; Takashi Akasaka; Kengo Kusano
Journal:  Heart Vessels       Date:  2016-07-28       Impact factor: 2.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.